In our case, due to the urothelial origin of the carcinoma, the lack of efficacy of polychemotherapy, the acquired resistance to osimertinib, and a positive PDL1 expression, a checkpoint inhibitor was initiated as third-line therapy. The gene discussed is CD274; the disease is carcinoma.